
    
      To allow subjects who have completed Insys 030 extension study (A multicenter, open-label,
      flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral
      Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure
      disorder who complete INS011-14-029 or Part A of INS011-15-054) to continue to take
      Cannabidiol oral solution.
    
  